Overall, the trials showed that a once-monthly intravenous dose of anifrolumab was able to reduce ... and the launch of a new subcutaneous injection formulation of the drug. AZ has previously ...

Patients on anifrolumab spent more time in remission and low disease activity, and reached those states more quickly, vs. placebo. Achieving these states can stave off permanent organ damage.

Zahi Touma, MD, PhD, from the University Health Network in Toronto, and colleagues examined whether anifrolumab plus SOC is associated with reduced organ damage accumulation compared with SOC only ...